Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Signs Bill Bolstering US FDA Device Center Funding By 2% To $8M

Executive Summary

The FDA’s device center is getting a 2% boost after President Trump on 20 December signed off on all appropriations bills for fiscal year 2020.

You may also be interested in...



Medtech Backs US Supreme Court Decision Upholding Affordable Care Act

Health care industry groups expressed support after the high court found that Texas and 17 other Republican-led states lacked standing to file suit because they hadn’t shown the act had directly harmed them.

AdvaMed Doubled Its Lobbying Spending Over Past Year

Medtech industry trade group AdvaMed spent more than $2m to help shape US congressional bills in the first quarter of 2020 – more than double what it spent to influence the course of legislation in the first quarter of 2019. Check out our in-depth analysis here.

Industry Advocacy Group Goes Global After Device Tax Repeal

After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT126046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel